Growth Hormone Treatment in Children With Prader-Willi Syndrome: Three Years of Longitudinal Data in Prepubertal Children and Adult Height Data From the KIGS Database.
Longitudinal data of children with Prader-Willi syndrome (PWS) treated with genotropin were registered in the Pfizer International Growth Database (KIGS).



To evaluate efficacy and safety of growth hormone (GH) treatment in a large group of children with PWS.



Data registered in KIGS from 1987 to 2012.



Worldwide retrospective cohort study.



Patients included 522 prepubertal children treated with GH for three years and 173 children who had reached adult height. Safety analysis included 2332 children. Intervention involved GH treatment.



Height standard deviation score (SDS), body mass index (BMI) SDS, occurrence of serious adverse events, and deaths reported in KIGS.



In prepubertal children, mean (standard deviation) height SDS improved to -0.31 (1.34) (P < 0.05) during three years of GH treatment. In the adolescent group, height SDS improved until the start of puberty to -0.22 (1.31) (P < 0.05) but had a loss of -0.77 (0.81) during puberty, resulting in a mean adult height SDS of -1.19 (1.37). Total height gain was 0.95 (1.32) SDS. BMI SDS increased in the prepubertal group from 1.11 (2.09) to 1.53 (1.43) (P < 0.05) and did not significantly change in the adolescent group, who had a BMI SDS at an adult height of 1.78 (1.26). KIGS contained 12 death reports.



GH treatment in children with PWS significantly improves linear growth. BMI remains on average below +2 SDS, in contrast to the natural course of increasing obesity in PWS. Safety should be closely monitored in children with PWS, with and without GH treatment.
Dutch Growth Research Foundation, 3016 AH Rotterdam, The Netherlands.|Children's Hospital Erasmus MC-Sophia, Department of Pediatrics, Division of Endocrinology, 3015 CN Rotterdam, The Netherlands.
Nienke E
NE
Bakker
Endocrine Care, Pfizer Health AB, 19190 Sollentuna, Sweden.
Anders
A
Lindberg
Pfizer Inc., New York, New York 10017.
Joseph
J
Heissler
Pfizer Inc., New York, New York 10017.
Hartmut A
HA
Wollmann
Pfizer Inc., New York, New York 10017.
Cecilia
C
Camacho-Hübner
Dutch Growth Research Foundation, 3016 AH Rotterdam, The Netherlands.|Children's Hospital Erasmus MC-Sophia, Department of Pediatrics, Division of Endocrinology, 3015 CN Rotterdam, The Netherlands.
Anita C
AC
Hokken-Koelega
D001827:Body Height; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D016208:Databases, Factual; D004393:Dwarfism, Pituitary / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D005260:Female; D006130:Growth Disorders / Q000188:drug therapy* / Q000209:etiology; D019382:Human Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007334:Insulin-Like Growth Factor I / Q000172:deficiency / Q000378:metabolism; D008137:Longitudinal Studies; D008297:Male; D011218:Prader-Willi Syndrome / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D011994:Recombinant Proteins / Q000627:therapeutic use*; D012189:Retrospective Studies
D011994:Recombinant Proteins; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I